CytomX Therapeutics Inc reports results for the quarter ended March 31 - Earnings Summary

• CytomX Therapeutics Inc CTMX.OQ reported quarterly adjusted earnings of 27 cents​​ per share for the quarter ended March 31, higher than the same quarter last year, when the company reported EPS of 17 cents. The mean expectation of five analysts for the quarter was for earnings of 12 cents per share. Wall Street expected results to range from -8 cents to 25 cents per share.

• Revenue rose 22.8% to $50.92 million from a year ago; analysts expected $30.84 million.

• CytomX Therapeutics Inc's reported EPS for the quarter was 27 cents​.

• The company reported quarterly net income of $23.53 million.

• CytomX Therapeutics Inc shares had risen by 46.0% this quarter and lost 9.9% so far this year.

FORECAST CHANGES

• The mean earnings estimate of analysts had risen by about 244.6% in the last three months.​

• In the last 30 days, there have been no negative revisions of earnings estimates

RECOMMENDATIONS

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 4 "strong buy" or "buy," 2 "hold" and no "sell" or "strong sell." The average consensus recommendation for the biotechnology & medical research peer group is also "buy"

• Wall Street's median 12-month price target for CytomX Therapeutics Inc is $3.50

This summary was machine generated from LSEG data May 12 at 01:32 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)